|
Title
|
|
|
|
High sera levels of SARS-CoV-2 N antigen are associated with death in hospitalized COVID-19 patients
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
French COVID Cohort Study Group
| |
|
Abstract
|
|
|
|
| The presence of free severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid-antigen in sera (N-antigenemia) has been shown in COVID-19 patients. However, the link between the quantitative levels of N-antigenemia and COVID-19 disease severity is not entirely understood. To assess the dynamics and clinical association of N-antigen sera levels with disease severity in COVID-19 patients, we analyzed data from patients included in the French COVID cohort, with at least one sera sample between January and September 2020. We assessed N-antigenemia levels and anti-N IgG titers, and patient outcomes was classified in two groups, survival or death. In samples collected within 8 days since symptom onset, we observed that deceased patients had a higher positivity rate (93% vs. 81%; p<0.001) and higher median levels of predicted N-antigenemia (2500 vs. 1200pg/mL; p<0.001) than surviving patients. Predicted time to N-antigen clearance in sera was prolonged in deceased patients compared to survivors (23.3 vs 19.3 days; p<0.0001). In a subset of patients with both sera and nasopharyngeal (NP) swabs, predicted time to N-antigen clearance in sera was prolonged in deceased patients (p<0.001), whereas NP viral load clearance did not differ between the groups (p=0.07). Our results demonstrate a strong relationship between N-antigenemia levels and COVID-19 severity on a prospective cohort. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal of medical virology. - New York, N.Y.
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2023
| |
|
ISSN
|
|
|
|
0146-6615
| |
|
DOI
|
|
|
|
10.1002/JMV.29247
| |
|
Volume/pages
|
|
|
|
95
:11
(2023)
, p. 1-6
| |
|
Article Reference
|
|
|
|
e29247
| |
|
ISI
|
|
|
|
001124416600053
| |
|
Pubmed ID
|
|
|
|
38009713
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|